Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand
Antibodies to programmed death-1 receptor and its ligand (anti–PD-1/PD-L1) produce durable responses in many cancers. However, the long-term effects of anti–PD-1/PD-L1 blockade are not well defined. We identified the toxicities, health outcomes and health-related quality of life (HRQoL) amongst long...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Patrinely, James Randall [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study - Hamzah, N. ELSEVIER, 2018, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:135 ; year:2020 ; pages:211-220 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ejca.2020.05.005 |
|---|
| Katalog-ID: |
ELV050852205 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV050852205 | ||
| 003 | DE-627 | ||
| 005 | 20230624170347.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200722s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2020.05.005 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica |
| 035 | |a (DE-627)ELV050852205 | ||
| 035 | |a (ELSEVIER)S0959-8049(20)30266-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.52 |2 bkl | ||
| 100 | 1 | |a Patrinely, James Randall |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand |
| 264 | 1 | |c 2020 | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Antibodies to programmed death-1 receptor and its ligand (anti–PD-1/PD-L1) produce durable responses in many cancers. However, the long-term effects of anti–PD-1/PD-L1 blockade are not well defined. We identified the toxicities, health outcomes and health-related quality of life (HRQoL) amongst long-term survivors treated with anti–PD-1/PD-L1. | ||
| 650 | 7 | |a Checkpoint inhibitors |2 Elsevier | |
| 650 | 7 | |a Pembrolizumab |2 Elsevier | |
| 650 | 7 | |a Renal cell carcinoma |2 Elsevier | |
| 650 | 7 | |a Lung cancer |2 Elsevier | |
| 650 | 7 | |a Nivolumab |2 Elsevier | |
| 650 | 7 | |a Melanoma |2 Elsevier | |
| 650 | 7 | |a Anti–PD-1 |2 Elsevier | |
| 650 | 7 | |a Toxicities |2 Elsevier | |
| 650 | 7 | |a Survivorship |2 Elsevier | |
| 650 | 7 | |a Quality of life |2 Elsevier | |
| 700 | 1 | |a Young, Arissa C. |4 oth | |
| 700 | 1 | |a Quach, Henry |4 oth | |
| 700 | 1 | |a Williams, Grant R. |4 oth | |
| 700 | 1 | |a Ye, Fei |4 oth | |
| 700 | 1 | |a Fan, Run |4 oth | |
| 700 | 1 | |a Horn, Leora |4 oth | |
| 700 | 1 | |a Beckermann, Kathryn E. |4 oth | |
| 700 | 1 | |a Gillaspie, Erin A. |4 oth | |
| 700 | 1 | |a Sosman, Jeffrey A. |4 oth | |
| 700 | 1 | |a Friedman, Debra L. |4 oth | |
| 700 | 1 | |a Moslehi, Javid J. |4 oth | |
| 700 | 1 | |a Johnson, Douglas B. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Hamzah, N. ELSEVIER |t The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |d 2018 |g Amsterdam [u.a.] |w (DE-627)ELV000241849 |
| 773 | 1 | 8 | |g volume:135 |g year:2020 |g pages:211-220 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2020.05.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 44.52 |j Therapie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 135 |j 2020 |h 211-220 |g 10 | ||
| author_variant |
j r p jr jrp |
|---|---|
| matchkey_str |
patrinelyjamesrandallyoungarissacquachhe:2020----:uvvrhpnmuehrpassigoiiisoyopstoadelheaeqaiyfiemnlntrsriosraewtat |
| hierarchy_sort_str |
2020 |
| bklnumber |
44.52 |
| publishDate |
2020 |
| allfields |
10.1016/j.ejca.2020.05.005 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica (DE-627)ELV050852205 (ELSEVIER)S0959-8049(20)30266-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Patrinely, James Randall verfasserin aut Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand 2020 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antibodies to programmed death-1 receptor and its ligand (anti–PD-1/PD-L1) produce durable responses in many cancers. However, the long-term effects of anti–PD-1/PD-L1 blockade are not well defined. We identified the toxicities, health outcomes and health-related quality of life (HRQoL) amongst long-term survivors treated with anti–PD-1/PD-L1. Checkpoint inhibitors Elsevier Pembrolizumab Elsevier Renal cell carcinoma Elsevier Lung cancer Elsevier Nivolumab Elsevier Melanoma Elsevier Anti–PD-1 Elsevier Toxicities Elsevier Survivorship Elsevier Quality of life Elsevier Young, Arissa C. oth Quach, Henry oth Williams, Grant R. oth Ye, Fei oth Fan, Run oth Horn, Leora oth Beckermann, Kathryn E. oth Gillaspie, Erin A. oth Sosman, Jeffrey A. oth Friedman, Debra L. oth Moslehi, Javid J. oth Johnson, Douglas B. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:135 year:2020 pages:211-220 extent:10 https://doi.org/10.1016/j.ejca.2020.05.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 135 2020 211-220 10 |
| spelling |
10.1016/j.ejca.2020.05.005 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica (DE-627)ELV050852205 (ELSEVIER)S0959-8049(20)30266-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Patrinely, James Randall verfasserin aut Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand 2020 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antibodies to programmed death-1 receptor and its ligand (anti–PD-1/PD-L1) produce durable responses in many cancers. However, the long-term effects of anti–PD-1/PD-L1 blockade are not well defined. We identified the toxicities, health outcomes and health-related quality of life (HRQoL) amongst long-term survivors treated with anti–PD-1/PD-L1. Checkpoint inhibitors Elsevier Pembrolizumab Elsevier Renal cell carcinoma Elsevier Lung cancer Elsevier Nivolumab Elsevier Melanoma Elsevier Anti–PD-1 Elsevier Toxicities Elsevier Survivorship Elsevier Quality of life Elsevier Young, Arissa C. oth Quach, Henry oth Williams, Grant R. oth Ye, Fei oth Fan, Run oth Horn, Leora oth Beckermann, Kathryn E. oth Gillaspie, Erin A. oth Sosman, Jeffrey A. oth Friedman, Debra L. oth Moslehi, Javid J. oth Johnson, Douglas B. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:135 year:2020 pages:211-220 extent:10 https://doi.org/10.1016/j.ejca.2020.05.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 135 2020 211-220 10 |
| allfields_unstemmed |
10.1016/j.ejca.2020.05.005 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica (DE-627)ELV050852205 (ELSEVIER)S0959-8049(20)30266-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Patrinely, James Randall verfasserin aut Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand 2020 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antibodies to programmed death-1 receptor and its ligand (anti–PD-1/PD-L1) produce durable responses in many cancers. However, the long-term effects of anti–PD-1/PD-L1 blockade are not well defined. We identified the toxicities, health outcomes and health-related quality of life (HRQoL) amongst long-term survivors treated with anti–PD-1/PD-L1. Checkpoint inhibitors Elsevier Pembrolizumab Elsevier Renal cell carcinoma Elsevier Lung cancer Elsevier Nivolumab Elsevier Melanoma Elsevier Anti–PD-1 Elsevier Toxicities Elsevier Survivorship Elsevier Quality of life Elsevier Young, Arissa C. oth Quach, Henry oth Williams, Grant R. oth Ye, Fei oth Fan, Run oth Horn, Leora oth Beckermann, Kathryn E. oth Gillaspie, Erin A. oth Sosman, Jeffrey A. oth Friedman, Debra L. oth Moslehi, Javid J. oth Johnson, Douglas B. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:135 year:2020 pages:211-220 extent:10 https://doi.org/10.1016/j.ejca.2020.05.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 135 2020 211-220 10 |
| allfieldsGer |
10.1016/j.ejca.2020.05.005 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica (DE-627)ELV050852205 (ELSEVIER)S0959-8049(20)30266-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Patrinely, James Randall verfasserin aut Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand 2020 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antibodies to programmed death-1 receptor and its ligand (anti–PD-1/PD-L1) produce durable responses in many cancers. However, the long-term effects of anti–PD-1/PD-L1 blockade are not well defined. We identified the toxicities, health outcomes and health-related quality of life (HRQoL) amongst long-term survivors treated with anti–PD-1/PD-L1. Checkpoint inhibitors Elsevier Pembrolizumab Elsevier Renal cell carcinoma Elsevier Lung cancer Elsevier Nivolumab Elsevier Melanoma Elsevier Anti–PD-1 Elsevier Toxicities Elsevier Survivorship Elsevier Quality of life Elsevier Young, Arissa C. oth Quach, Henry oth Williams, Grant R. oth Ye, Fei oth Fan, Run oth Horn, Leora oth Beckermann, Kathryn E. oth Gillaspie, Erin A. oth Sosman, Jeffrey A. oth Friedman, Debra L. oth Moslehi, Javid J. oth Johnson, Douglas B. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:135 year:2020 pages:211-220 extent:10 https://doi.org/10.1016/j.ejca.2020.05.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 135 2020 211-220 10 |
| allfieldsSound |
10.1016/j.ejca.2020.05.005 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica (DE-627)ELV050852205 (ELSEVIER)S0959-8049(20)30266-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.52 bkl Patrinely, James Randall verfasserin aut Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand 2020 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Antibodies to programmed death-1 receptor and its ligand (anti–PD-1/PD-L1) produce durable responses in many cancers. However, the long-term effects of anti–PD-1/PD-L1 blockade are not well defined. We identified the toxicities, health outcomes and health-related quality of life (HRQoL) amongst long-term survivors treated with anti–PD-1/PD-L1. Checkpoint inhibitors Elsevier Pembrolizumab Elsevier Renal cell carcinoma Elsevier Lung cancer Elsevier Nivolumab Elsevier Melanoma Elsevier Anti–PD-1 Elsevier Toxicities Elsevier Survivorship Elsevier Quality of life Elsevier Young, Arissa C. oth Quach, Henry oth Williams, Grant R. oth Ye, Fei oth Fan, Run oth Horn, Leora oth Beckermann, Kathryn E. oth Gillaspie, Erin A. oth Sosman, Jeffrey A. oth Friedman, Debra L. oth Moslehi, Javid J. oth Johnson, Douglas B. oth Enthalten in Elsevier Hamzah, N. ELSEVIER The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study 2018 Amsterdam [u.a.] (DE-627)ELV000241849 volume:135 year:2020 pages:211-220 extent:10 https://doi.org/10.1016/j.ejca.2020.05.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.52 Therapie Medizin VZ AR 135 2020 211-220 10 |
| language |
English |
| source |
Enthalten in The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study Amsterdam [u.a.] volume:135 year:2020 pages:211-220 extent:10 |
| sourceStr |
Enthalten in The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study Amsterdam [u.a.] volume:135 year:2020 pages:211-220 extent:10 |
| format_phy_str_mv |
Article |
| bklname |
Therapie |
| institution |
findex.gbv.de |
| topic_facet |
Checkpoint inhibitors Pembrolizumab Renal cell carcinoma Lung cancer Nivolumab Melanoma Anti–PD-1 Toxicities Survivorship Quality of life |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| authorswithroles_txt_mv |
Patrinely, James Randall @@aut@@ Young, Arissa C. @@oth@@ Quach, Henry @@oth@@ Williams, Grant R. @@oth@@ Ye, Fei @@oth@@ Fan, Run @@oth@@ Horn, Leora @@oth@@ Beckermann, Kathryn E. @@oth@@ Gillaspie, Erin A. @@oth@@ Sosman, Jeffrey A. @@oth@@ Friedman, Debra L. @@oth@@ Moslehi, Javid J. @@oth@@ Johnson, Douglas B. @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000241849 |
| dewey-sort |
3610 |
| id |
ELV050852205 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV050852205</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624170347.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200722s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejca.2020.05.005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV050852205</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0959-8049(20)30266-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Patrinely, James Randall</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Antibodies to programmed death-1 receptor and its ligand (anti–PD-1/PD-L1) produce durable responses in many cancers. However, the long-term effects of anti–PD-1/PD-L1 blockade are not well defined. We identified the toxicities, health outcomes and health-related quality of life (HRQoL) amongst long-term survivors treated with anti–PD-1/PD-L1.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Checkpoint inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pembrolizumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Renal cell carcinoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lung cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nivolumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Melanoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti–PD-1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Toxicities</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Survivorship</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Quality of life</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Young, Arissa C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quach, Henry</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Williams, Grant R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ye, Fei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fan, Run</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Horn, Leora</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Beckermann, Kathryn E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gillaspie, Erin A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sosman, Jeffrey A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Friedman, Debra L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moslehi, Javid J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Johnson, Douglas B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Hamzah, N. ELSEVIER</subfield><subfield code="t">The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000241849</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:135</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:211-220</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejca.2020.05.005</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">135</subfield><subfield code="j">2020</subfield><subfield code="h">211-220</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| author |
Patrinely, James Randall |
| spellingShingle |
Patrinely, James Randall ddc 610 bkl 44.52 Elsevier Checkpoint inhibitors Elsevier Pembrolizumab Elsevier Renal cell carcinoma Elsevier Lung cancer Elsevier Nivolumab Elsevier Melanoma Elsevier Anti–PD-1 Elsevier Toxicities Elsevier Survivorship Elsevier Quality of life Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand |
| authorStr |
Patrinely, James Randall |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000241849 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.52 bkl Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand Checkpoint inhibitors Elsevier Pembrolizumab Elsevier Renal cell carcinoma Elsevier Lung cancer Elsevier Nivolumab Elsevier Melanoma Elsevier Anti–PD-1 Elsevier Toxicities Elsevier Survivorship Elsevier Quality of life Elsevier |
| topic |
ddc 610 bkl 44.52 Elsevier Checkpoint inhibitors Elsevier Pembrolizumab Elsevier Renal cell carcinoma Elsevier Lung cancer Elsevier Nivolumab Elsevier Melanoma Elsevier Anti–PD-1 Elsevier Toxicities Elsevier Survivorship Elsevier Quality of life |
| topic_unstemmed |
ddc 610 bkl 44.52 Elsevier Checkpoint inhibitors Elsevier Pembrolizumab Elsevier Renal cell carcinoma Elsevier Lung cancer Elsevier Nivolumab Elsevier Melanoma Elsevier Anti–PD-1 Elsevier Toxicities Elsevier Survivorship Elsevier Quality of life |
| topic_browse |
ddc 610 bkl 44.52 Elsevier Checkpoint inhibitors Elsevier Pembrolizumab Elsevier Renal cell carcinoma Elsevier Lung cancer Elsevier Nivolumab Elsevier Melanoma Elsevier Anti–PD-1 Elsevier Toxicities Elsevier Survivorship Elsevier Quality of life |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a c y ac acy h q hq g r w gr grw f y fy r f rf l h lh k e b ke keb e a g ea eag j a s ja jas d l f dl dlf j j m jj jjm d b j db dbj |
| hierarchy_parent_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| hierarchy_parent_id |
ELV000241849 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000241849 |
| title |
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand |
| ctrlnum |
(DE-627)ELV050852205 (ELSEVIER)S0959-8049(20)30266-5 |
| title_full |
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand |
| author_sort |
Patrinely, James Randall |
| journal |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| journalStr |
The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
211 |
| author_browse |
Patrinely, James Randall |
| container_volume |
135 |
| physical |
10 |
| class |
610 VZ 44.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Patrinely, James Randall |
| doi_str_mv |
10.1016/j.ejca.2020.05.005 |
| dewey-full |
610 |
| title_sort |
survivorship in immune therapy: assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand |
| title_auth |
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand |
| abstract |
Antibodies to programmed death-1 receptor and its ligand (anti–PD-1/PD-L1) produce durable responses in many cancers. However, the long-term effects of anti–PD-1/PD-L1 blockade are not well defined. We identified the toxicities, health outcomes and health-related quality of life (HRQoL) amongst long-term survivors treated with anti–PD-1/PD-L1. |
| abstractGer |
Antibodies to programmed death-1 receptor and its ligand (anti–PD-1/PD-L1) produce durable responses in many cancers. However, the long-term effects of anti–PD-1/PD-L1 blockade are not well defined. We identified the toxicities, health outcomes and health-related quality of life (HRQoL) amongst long-term survivors treated with anti–PD-1/PD-L1. |
| abstract_unstemmed |
Antibodies to programmed death-1 receptor and its ligand (anti–PD-1/PD-L1) produce durable responses in many cancers. However, the long-term effects of anti–PD-1/PD-L1 blockade are not well defined. We identified the toxicities, health outcomes and health-related quality of life (HRQoL) amongst long-term survivors treated with anti–PD-1/PD-L1. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand |
| url |
https://doi.org/10.1016/j.ejca.2020.05.005 |
| remote_bool |
true |
| author2 |
Young, Arissa C. Quach, Henry Williams, Grant R. Ye, Fei Fan, Run Horn, Leora Beckermann, Kathryn E. Gillaspie, Erin A. Sosman, Jeffrey A. Friedman, Debra L. Moslehi, Javid J. Johnson, Douglas B. |
| author2Str |
Young, Arissa C. Quach, Henry Williams, Grant R. Ye, Fei Fan, Run Horn, Leora Beckermann, Kathryn E. Gillaspie, Erin A. Sosman, Jeffrey A. Friedman, Debra L. Moslehi, Javid J. Johnson, Douglas B. |
| ppnlink |
ELV000241849 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ejca.2020.05.005 |
| up_date |
2024-07-06T18:38:57.067Z |
| _version_ |
1803855999343263744 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV050852205</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624170347.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200722s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejca.2020.05.005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001600.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV050852205</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0959-8049(20)30266-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Patrinely, James Randall</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Antibodies to programmed death-1 receptor and its ligand (anti–PD-1/PD-L1) produce durable responses in many cancers. However, the long-term effects of anti–PD-1/PD-L1 blockade are not well defined. We identified the toxicities, health outcomes and health-related quality of life (HRQoL) amongst long-term survivors treated with anti–PD-1/PD-L1.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Checkpoint inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pembrolizumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Renal cell carcinoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lung cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nivolumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Melanoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti–PD-1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Toxicities</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Survivorship</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Quality of life</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Young, Arissa C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quach, Henry</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Williams, Grant R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ye, Fei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fan, Run</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Horn, Leora</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Beckermann, Kathryn E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gillaspie, Erin A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sosman, Jeffrey A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Friedman, Debra L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moslehi, Javid J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Johnson, Douglas B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Hamzah, N. ELSEVIER</subfield><subfield code="t">The effect of early cognitive therapy in improving cognitive functions using neuropsychology and diffusion tensor imaging measurements following mild traumatic brain injury: A pilot study</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000241849</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:135</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:211-220</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejca.2020.05.005</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">135</subfield><subfield code="j">2020</subfield><subfield code="h">211-220</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| score |
7.4010878 |